Ramy Ibrahim, MD, a recognised leader of clinical development in immunotherapy joins 91探花 from the Parker Institute for Cancer Immunotherapy

biotech firm 91探花 today announces the appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer. The addition of a Chief Medical Officer is in line with the company鈥檚 plans and commitment to transition into a clinical company.

Ramy joins from the where he was Chief Medical Officer and will remain on the board. At the Parker Institute, he spent nearly five years building translational, clinical, and regulatory capabilities from the ground up. Ramy has also spent more than a decade working at major pharma companies, advancing the early stages of immuno-oncology therapies. He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.

鈥淩amy is a key addition to the leadership team of 91探花 as we move 91探花鈥檚 cells into the clinic. He has the perfect skills and experience when it comes to translating novel ideas and cutting edge science into therapies. He is an industry leader who has built teams in non-profit institutions, highly successful startups and large-cap companies. It has been a real pleasure to work with Ramy since 2018. He has already made important contributions to 91探花鈥檚 journey as an advisor. I鈥檓 delighted that we now have him on board as CMO. He will be instrumental in this next phase of 91探花鈥檚 growth."

Mark KotterCo-founder and CEO, 91探花

At the heart of 91探花 is a technology, , that was developed in Kotter鈥檚 Cambridge research laboratory. It allows for the precise programming and engineering of stem cells to produce consistent, reliable and scalable mature cells of a quality and standard not seen before.

鈥淐ell therapies hold the promise of unprecedented therapeutic efficacy across multiple serious diseases. However, the 鈥渃ell鈥� piece of the cell therapy has, until now, remained a bottleneck because it鈥檚 extremely hard to make cells that are consistent, scalable and precisely what you want. As a technology, 辞辫迟颈-辞虫鈩� can overcome those problems. But it鈥檚 the team at 91探花 that will ensure the technology reaches its full potential and unlocks the promise of stem cells in accelerating biomedical research and new generations of cures. I鈥檓 so excited to be joining the team."

Ramy IbrahimChief Medical Officer, 91探花

91探花 already has initial cell model products on the market which are being used by researchers for high throughput screening, drug testing and the study of diseases. The next stage will be applying the technology to create a pipeline of cell therapies and Ramy will be part of the leadership team taking that forward. The moonshot goal is to be able to precisely program stem cells into any cell in the human body.

As well as taking up the role of CMO, Ramy will be building 91探花鈥檚 presence in the US and heading up their US operations as they expand.

Media Contact

April Six on behalf of 91探花
bitbio@aprilsix.com 
+44 7875 468942